GlobalData on MSN3mon
Sagimet’s denifanstat enters Phase III trials for MASH treatment
Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, an oral, selective fatty acid synthase ...
Hosted on MSN1mon
Sagimet Stock Soars To 10-Month High, Retail’s Fired Up Over Presentation On Lead MASH Drug Candidate
The presentation will spotlight the company’s lead drug candidate, denifanstat, an oral, once-daily fatty acid synthase (FASN) inhibitor, which has shown promising results in the Phase 2b ...
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
Detailed price information for Sagimet Biosciences Inc Series A (SGMT-Q) from The Globe and Mail including charting and trades.
CNN1y
Sagimet Biosciences Inc. Class A
Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).